Phase 2 PTSD Trial, Recruiting NCT02560805 Sponsor: Emory University Condition: PTSD
Back to Ptsd

Phase 2 PTSD Trial, Recruiting

NCT02560805
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Veterans between the ages of 18 and 65 years old, either with PTSD or without PTSD (the group without PTSD serves as a comparison group, matched by age, gender, and race).

Who may not be able to join:

  • People who are currently pregnant
  • People who have high blood pressure (hypertension)
  • People who have diabetes
  • People who have heart or blood vessel disease
  • People who use illegal drugs
  • People who drink more than 2 alcoholic drinks per day
  • People who have high cholesterol or high levels of fats in the blood (hyperlipidemia)
  • People who have problems with the part of the nervous system that controls automatic body functions, such as heart rate and blood pressure (confirm with trial site)
  • People currently taking certain blood pressure or heart medications, including clonidine, beta blockers, ACE inhibitors, or ARBs
  • People who have taken a type of antidepressant called MAO inhibitors within the last 14 days
  • People who have any serious ongoing illness or disease
  • People with chronic kidney disease where the kidneys are not filtering blood well enough (confirm with trial site)
  • People with higher-than-normal potassium levels in their blood
  • People with a systolic (top number) blood pressure reading below 100
  • People with a diastolic (bottom number) blood pressure reading below 60
  • People with a resting heart rate below 50 beats per minute
  • People with a known allergy or sensitivity to ARB medications or beta blocker medications

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jeanie Park, MD, Emory University

Phone: 404-321-6111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 October 2015
Est. completion
30 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Muscle Sympathetic Nerve Activity (MSNA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov